The Autoimmune Disease Most Doctors Aren’t Looking For

For anyone who has been told their dryness, fatigue, and joint pain are just aging, and sensed there was something more to the story.

You’ve probably been told it’s stress. Or perimenopause. Or just getting older.

But if you wake up at night reaching for water, spend your mornings with eyes that feel like sandpaper, and carry a fatigue that no amount of sleep seems to fix, those symptoms aren’t separate problems. They are one condition. And most doctors aren’t connecting them.

It’s called Sjögren’s disease, and it is the second most common autoimmune rheumatic disease in the world. Over 90% of those diagnosed are women [1]. Most of them waited years to get a name for what they were experiencing, because each symptom was routed to a different specialist and nobody looked at the whole picture.

One detail that surprises many people: up to 22% of Sjögren’s patients have co-existing thyroid disease [1]. If you’ve been managing a thyroid condition, whether Hashimoto’s or another thyroid diagnosis, and you still don’t feel right despite treatment, there may be a reason your doctors haven’t found yet. Sjögren’s is frequently the missing piece.

The diagnostic delay is significant. Patients routinely wait years, sometimes more than a decade, between their first symptoms and a formal diagnosis [2]. In that time they collect referrals: to ophthalmology for dry eyes, to dentistry for cavities that keep returning, to rheumatology for joint pain that doesn’t fit a pattern, to psychiatry for fatigue and depression. Each specialist treats their piece. Nobody looks at the whole picture.

This article is about what that picture actually looks like, and what to do when you recognize yourself in it.

Part 1: Recognizing the Pattern

Why Sjögren’s Is So Easy to Miss

In 2024, the British Society for Rheumatology published a comprehensive updated management guideline that formally shifted the terminology from “Sjögren’s syndrome” to “Sjögren’s disease.” The name change is deliberate and important [1]. Syndrome implies a loose collection of symptoms. Disease acknowledges what this actually is: a defined, chronic autoimmune condition with systemic consequences. That distinction matters for how seriously it is taken, by clinicians and by patients alike.

Sjögren’s disease occurs when the immune system attacks the glands that produce moisture throughout the body, primarily the tear glands and salivary glands, but not only those. It’s an inflammatory process driven by immune cells infiltrating glandular tissue and disrupting its ability to function. Because those glands are present throughout the body, including the eyes, mouth, nose, throat, airways, skin, and vagina, the symptoms can appear in a bewildering range of places that don’t obviously point to a single cause.

This is exactly why it gets missed. Each symptom gets routed to the specialist for that body part. The ophthalmologist treats the dry eyes as dry eye disease. The dentist treats the decay from reduced saliva. The rheumatologist may or may not consider autoimmune disease. The GP sees fatigue, orders a basic panel that comes back unremarkable, and moves on. Nobody says: wait, these belong together.

The Full Symptom Picture

Most people know Sjögren’s as the dry eyes and dry mouth disease. But the symptom profile is considerably broader than that, and the symptoms most likely to be dismissed — fatigue, brain fog, joint pain — are the ones most likely to delay diagnosis.

Sicca symptoms refer to dryness of the eyes (grittiness, burning, light sensitivity, blurred vision), dryness of the mouth (difficulty chewing dry foods, altered taste, needing water to swallow, waking at night to drink), and dryness of the nose, throat, airways, and skin. These are the hallmark features. But many patients with established Sjögren’s have mild or atypical dryness, symptoms so gradual they’ve been normalized over years.

Fatigue in Sjögren’s is not ordinary tiredness. It is one of the most debilitating features of the disease and one of the most frequently dismissed. Clinical medicine has few tools to assess or treat fatigue well, and this symptom has driven more Sjögren’s patients into misdiagnosis as depression, fibromyalgia, or functional disorder than almost any other feature [2]. If your fatigue has been attributed to everything except an autoimmune process, Sjögren’s belongs in the differential.

Cognitive symptoms, what patients often describe as brain fog, include difficulty concentrating, word-finding problems, memory lapses, and a mental slowness that wasn’t there before. These are documented features of Sjögren’s disease with real neurological underpinnings. They are also among the symptoms most likely to be attributed to anxiety, depression, or middle age.

Joint pain and stiffness tend to affect the small joints of the hands and wrists. The pain is often migratory, moving between joints, and intermittent. It is not typically the destructive joint disease seen in rheumatoid arthritis, but it is real, recurrent, and impactful.

Peripheral neuropathy, meaning tingling, numbness, or burning sensations in the hands or feet, is an underrecognized feature of Sjögren’s that frequently leads to neurology referrals and inconclusive workups before the autoimmune root is identified.

Recurrent dental decay is another common early sign. Reduced saliva dramatically increases cavity risk. Patients with Sjögren’s often describe a sudden change in their dental health — previously well-maintained teeth deteriorating rapidly — which is sometimes the first signal that something systemic has shifted.

The overlap picture matters too. Sjögren’s disease occurs both as a standalone condition (primary Sjögren’s) and alongside other autoimmune conditions including rheumatoid arthritis, lupus, and systemic sclerosis. It also overlaps significantly with thyroid disease: in population-based registries, up to 22% of Sjögren’s patients have co-existing thyroid disease [1]. If you have Hashimoto’s and your symptoms feel broader than thyroid dysfunction alone, Sjögren’s is worth investigating.

Who Is Most at Risk

Sjögren’s disease is diagnosed most commonly in women between the ages of 40 and 60, but it can present at any age including in young adults and adolescents. The 2024 BSR guideline covers management across all ages for the first time, acknowledging this broader range [1]. Family history of autoimmune disease increases risk. Hormonal transitions, particularly perimenopause, appear to be a triggering or worsening factor in some patients, though the mechanisms are still being studied.

Part 2: This Is Not in Your Head

The Years That Get Lost

In patient surveys and clinical studies, a significant proportion of Sjögren’s patients report a delay of five years or more between symptom onset and diagnosis [2]. Five years of dry eyes being treated as environmental. Five years of fatigue being attributed to stress or perimenopause. Five years of dental decay with no explanation. Five years of brain fog that nobody could account for.

Sjögren’s patients report being told for years that they have functional disorders, fibromyalgia, depression, or difficult menopause. These conditions may co-occur with Sjögren’s, and they are frequently blamed for symptoms that are primarily caused by the disease itself.

I want to name what happens to a person during those years. Not just the physical progression of the disease, though untreated Sjögren’s does progress and the consequences of delayed diagnosis include increased risk of dental damage, corneal damage, and systemic complications. I mean what happens to the person’s relationship with their own body. The gradual erosion of confidence that comes from describing symptoms accurately and being sent home repeatedly without answers. The self-blame. The wondering whether it’s all in your head.

It isn’t. The fact that a 2024 major society guideline now formally emphasizes early recognition and interdisciplinary diagnosis as priorities, not exceptions, tells you that medicine is beginning to reckon with the cost of getting this wrong [1].

Part 3: What Good Testing Actually Looks Like

This section gets more clinical. You don’t need to absorb all of it today. If you’ve just been diagnosed and your head is still spinning, bookmark this and bring it to your next appointment. It’s written to help you know what questions to ask and what to expect, not to overwhelm you.

The Diagnostic Workup

Diagnosing Sjögren’s disease requires putting several pieces together. No single test confirms it. The 2016 ACR/EULAR classification criteria, now widely used in clinical diagnosis, incorporate blood tests, eye assessment, and tissue biopsy into a scoring system [1]. Here’s what a thorough evaluation includes.

Anti-SSA/Ro antibodies are the most clinically useful blood test in Sjögren’s. They are present in approximately 60 to 70% of people with primary Sjögren’s disease. Their presence alongside sicca symptoms and fatigue is a strong signal. Their absence does not rule out the diagnosis. A meaningful proportion of patients are seronegative and still have confirmed disease [1].

Anti-SSB/La antibodies are less sensitive than anti-SSA but add specificity when positive. They are usually ordered at the same time.

ANA (antinuclear antibody) is a general autoimmune screen. It is positive in the majority of Sjögren’s patients but nonspecific on its own. A positive ANA alongside sicca symptoms and fatigue should prompt more targeted antibody testing.

Full blood count, ESR, and CRP are systemic inflammation markers. ESR is more commonly elevated in Sjögren’s than CRP. Anemia, low white cell count, and low platelets can all occur and reflect systemic disease involvement.

Serum immunoglobulins — elevated IgG is a common finding in Sjögren’s, reflecting chronic immune activation, and is used to monitor disease over time.

Rheumatoid factor is positive in approximately 40% of Sjögren’s patients. Its presence alongside sicca symptoms should prompt consideration of Sjögren’s even without the classic dry eye and dry mouth presentation.

Ocular surface assessment by an ophthalmologist or optometrist experienced in dry eye disease should include Schirmer’s test to measure tear production, and ocular staining with fluorescein and lissamine green to assess corneal and conjunctival damage. These findings are scored components of the ACR/EULAR diagnostic criteria [1].

Minor salivary gland biopsy involves a small tissue sample taken from the inner lower lip, assessed for the characteristic lymphocytic infiltration that is the hallmark of Sjögren’s disease. This is the most specific diagnostic test available and is recommended when antibody testing is negative but clinical suspicion remains high [1]. It is a minor outpatient procedure.

Salivary flow assessment measures unstimulated whole saliva production. Very low flow rates in the context of other features contribute to the diagnostic score.

Thyroid panel including TPO antibodies is part of our standard workup given the high rate of co-existing thyroid disease in Sjögren’s patients.

Part 4: What Actually Moves the Needle

Managing Sjögren’s: The Whole Picture

There is currently no cure for Sjögren’s disease and no disease-modifying treatment with the same evidence base as exists for rheumatoid arthritis. But “no cure” is not the same as “nothing helps.” The 2024 BSR guideline frames management around empowering individuals to manage their condition through conserving and replacing secretions, preventing damage, and where needed suppressing systemic disease activity [1]. That is a practical and genuinely useful framework.

Moisture management comes first. Preservative-free artificial tears used frequently throughout the day, not just when uncomfortable, are the foundation of eye management. Cyclosporine eye drops (Restasis) and lifitegrast (Xiidra) target the inflammatory component of Sjögren’s dry eye and have meaningful evidence for reducing symptoms and protecting the ocular surface. Punctal plugs are tiny inserts that block the drainage canals in the eyelids, reducing tear loss. They are simple, reversible, and effective for many patients.

For the mouth: regular sips of water, sugar-free gum and lozenges to stimulate saliva, saliva substitutes at night, and meticulous dental hygiene with fluoride toothpaste and regular professional care. The connection between Sjögren’s and accelerated dental decay is not widely communicated to patients, and it should be. Prevention is far more effective than repair.

The Integrative Approach: What the Evidence Actually Shows

Omega-3 fatty acids, specifically EPA and DHA, have been studied for Sjögren’s-associated dry eye disease, and the biological rationale is sound. Omega-3 fatty acids modulate the inflammatory cascade that damages lacrimal gland function and the ocular surface. It’s worth understanding both what the evidence supports and where it’s less certain, because the picture is more nuanced than it is sometimes presented.

Earlier trials, including a well-designed multicenter study by Epitropoulos et al., found that oral re-esterified omega-3 supplementation significantly improved tear osmolarity, tear break-up time, and inflammatory markers in patients with dry eye and meibomian gland dysfunction [3]. That study, along with several others, shaped early enthusiasm for omega-3 as a dry eye intervention.

The DREAM trial, a larger and more rigorous double-masked randomized controlled trial published in the New England Journal of Medicine in 2018, found that omega-3 supplementation was not significantly better than an olive oil placebo for dry eye disease outcomes [4]. This was an important finding that tempered the field’s earlier confidence. It is worth noting that the DREAM trial enrolled patients with general dry eye disease rather than specifically Sjögren’s-associated dry eye, and some researchers have raised questions about whether the olive oil placebo was truly inert given its own anti-inflammatory properties.

Clinically, omega-3 supplementation carries an excellent safety profile, supports cardiovascular and general anti-inflammatory health, and remains a reasonable adjunct for Sjögren’s patients, particularly those with concurrent meibomian gland dysfunction. We discuss it with patients as a low-risk option with plausible benefit and mixed direct evidence, rather than a proven first-line treatment. The anti-inflammatory dietary rationale remains solid even if the isolated supplement evidence is contested.

Vitamin D deficiency is consistently more prevalent in Sjögren’s patients than in matched controls, and lower vitamin D levels have been associated with higher disease activity in several studies [5, 6]. A 2023 systematic review and meta-analysis pooling data from nine clinical studies found a significantly higher prevalence of vitamin D insufficiency in Sjögren’s disease patients compared to healthy controls [5]. The proposed mechanism involves vitamin D’s role as an immune modulator: it promotes tolerance and dampens the kind of autoreactive immune activity that drives Sjögren’s pathology.

In clinical practice, we aim to optimize vitamin D levels rather than simply correct frank deficiency. My recommended target level is in the 50 to 70 ng/mL range. This is an area where clinical opinion varies and the optimal threshold for autoimmune benefit has not been established in randomized trials, so it’s worth an honest conversation with your provider about what target makes sense for you.

An anti-inflammatory dietary pattern is another cornerstone. The Mediterranean pattern reduces systemic inflammatory burden, supports gut microbiome diversity, and provides the polyphenols that modulate immune function. There is no randomized trial specifically in Sjögren’s disease, but the anti-inflammatory dietary evidence in autoimmune disease more broadly is consistent. Reducing ultra-processed food, refined sugar, and pro-inflammatory oils while increasing olive oil, fish, legumes, and vegetables is a defensible and low-risk step for every patient with an inflammatory autoimmune condition.

Hydroxychloroquine (Plaquenil) is the most commonly prescribed systemic medication for Sjögren’s disease, and it’s worth being honest about both what it does and what it doesn’t do. It is an antimalarial used in autoimmune disease for decades and is generally well tolerated [1]. The 2024 BSR guideline recommends it particularly for systemic features including joint pain (arthralgia), skin vasculitis (purpura), and elevated inflammatory markers [1]. These are the indications where clinical experience is most consistent.

However, the JOQUER trial, a double-blind randomized controlled trial specifically designed to evaluate hydroxychloroquine for the primary symptoms of Sjögren’s disease, found no significant benefit over placebo for dryness, fatigue, or pain at 24 weeks [7]. This doesn’t mean hydroxychloroquine has no role, and the 2024 BSR guideline continues to support its use for systemic features. But it does mean that if you are taking it primarily hoping to improve dryness or fatigue, it may not be delivering what you expect. This is a conversation worth having directly with your rheumatologist about what specifically it is being prescribed to address in your case.

Pilocarpine and cevimeline are medications that stimulate secretion from functioning glandular tissue, increasing both saliva and tear production in patients with residual glandular function. Pilocarpine has good evidence for both dry mouth and dry eye in Sjögren’s [1]. Side effects including flushing, sweating, and increased urination can limit use for some patients, but they are worth discussing if moisture symptoms are significantly affecting your daily life.

Fatigue management is formally acknowledged in the 2024 BSR guideline as a priority target, not a side issue [1]. The approach is multimodal: identify and treat contributing factors such as thyroid disease, anemia, sleep disruption, depression, and pain; consider hydroxychloroquine if not already prescribed; and address sleep quality directly. Structured activity pacing, a technique developed in chronic fatigue management, can help patients avoid the boom-and-bust cycle of overexertion followed by crash.

Neuropathy management requires early recognition. For patients with peripheral neuropathy, referral to a neurologist with experience in autoimmune neuropathy is important. Immunoglobulin therapy has evidence for the most severe forms. For milder sensory symptoms, optimizing vitamin B12, vitamin D, and omega-3 status is a reasonable starting point.

Emerging therapies. For the first time, there is genuine momentum toward a targeted treatment for Sjögren's disease. Ianalumab, a monoclonal antibody in development by Novartis, works through a dual mechanism: depleting overactive B cells and blocking the BAFF receptor, a key driver of the immune dysfunction underlying the disease. Both Phase III trials met their primary endpoint in 2025, and regulatory submission is expected to follow. It is not yet approved, but for patients with moderate to severe systemic disease, it is worth asking your rheumatologist about as the landscape develops.

A note on lymphoma risk. This is a conversation patients deserve to have and often don’t. Sjögren’s disease carries an elevated lifetime risk of B-cell lymphoma compared to the general population. Multiple studies estimate approximately 5% lifetime risk in primary Sjögren’s, reflecting a roughly 10-fold relative increase [1]. This is not a reason to panic. The large majority of patients with Sjögren’s never develop lymphoma. But it is a reason for regular monitoring, and it is why persistent enlarged lymph nodes, unexplained fevers, or night sweats in a Sjögren’s patient warrant prompt investigation rather than watchful waiting.

Part 5: Retesting and What to Watch

The 6-Month and Annual Framework

At diagnosis baseline, a thorough workup includes the full antibody panel (anti-SSA, anti-SSB, ANA, rheumatoid factor), full blood count, ESR, CRP, immunoglobulins, complete metabolic panel, full thyroid panel including TPO antibodies, vitamin D, B12, and iron studies.

At 6 months, repeat inflammatory markers (ESR, CRP) and full blood count, and assess symptom response to any initiated treatments. If hydroxychloroquine was started, an eye examination establishes baseline retinal status before long-term use. Rare retinal toxicity with prolonged high-dose hydroxychloroquine is monitored with annual eye exams once treatment is established.

Annually, a full panel review, ophthalmology assessment for ocular surface status, dental review with awareness of Sjögren’s-associated decay risk, and clinical assessment for any new systemic features including lymph node changes, unexplained weight loss, and new neuropathy symptoms.

At home, tracking dry eye symptoms (severity, frequency, and impact on activities), mouth dryness and dental health, fatigue levels, joint symptoms, and any cognitive changes gives both you and your clinical team a clearer picture over time. A symptom diary is specifically recommended in the 2024 BSR guideline as a tool for monitoring treatment response [1].

Return sooner than scheduled if you notice new lymph node enlargement that doesn’t resolve within a few weeks, unexplained fever, night sweats, significant unexplained weight loss, a sudden worsening of any established symptom, or new neurological symptoms such as significant weakness, loss of coordination, or vision changes beyond typical Sjögren’s dry eye.

What to Ask For

If you’ve been managing dry eyes, dry mouth, fatigue, and joint pain in separate specialist silos, ask directly: has anyone checked anti-SSA and anti-SSB antibodies? Has anyone considered whether these symptoms might represent a single autoimmune process? These are not specialist-only questions. They can and should be raised with your GP or primary care provider.

If antibody testing comes back negative but your symptoms are strong, ask about a minor salivary gland biopsy. A negative antibody test does not rule out Sjögren’s disease, and the biopsy is the most specific diagnostic tool available [1].

Where to Go From Here

Sjögren’s disease is not a diagnosis that means a lifetime of progressive decline without recourse. It is a chronic condition that responds meaningfully to the right management: moisture protection, anti-inflammatory interventions, systemic treatment where indicated, and careful monitoring.

What patients with Sjögren’s need most, and receive least, is a clinician who understands that the symptom picture belongs together. The dry eyes, the dry mouth, the fatigue, the brain fog, the joint pain, and the dental changes are not separate problems that happen to exist in the same person. They are one disease expressing itself across multiple systems.

You deserve to have someone look at the whole picture. If you’ve been managing the pieces separately and the pieces don’t fully explain how you feel, that’s the conversation worth having.

Book a Consultation with Heal Integrative Wellness